Breaking News
Investing Pro 0
NEW! Get Actionable Insights with InvestingPro+ Try 7 Days Free

Flush with cash, Pfizer buys Global Blood Therapeutics in $5.4 billion deal

Stock Markets Aug 08, 2022 07:10PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters. FILE PHOTO: Pfizer logo and stock graph are seen in this illustration taken, May 1, 2022. REUTERS/Dado Ruvic/Illustration/File Photo
 
PFE
+0.72%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
GBT
+0.01%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 

By Mrinalika Roy and Michael Erman

(Reuters) - Pfizer Inc (NYSE:PFE) on Monday agreed to pay $5.4 billion in cash for sickle cell disease drugmaker Global Blood Therapeutics (NASDAQ:GBT), as it looks to capitalize on a surge in revenue from its COVID-19 vaccine and treatment.

Pfizer will pay $68.50 per GBT share, which represents a 7.3% premium to its Friday closing price and a nearly 43% premium over Thursday's closing price after Bloomberg reported that GBT had attracted takeover interest. The Wall Street Journal reported on Friday that Pfizer was in advanced talks to buy it.

Pfizer's 2021 revenue of $81.3 billion was nearly double the mark from the previous year, due to COVID-19 vaccine sales. With the addition of its COVID-19 antiviral pill Paxlovid, Pfizer is expected to generate around $100 billion in revenue this year, but sales from both products are expected to decline going forward.

Pfizer has been on the lookout for acquisitions that could bring in billions in annual sales by the end of the decade.

"We have very deliberately taken a strategy of diversification in our M&A deals," Aamir Malik, Pfizer's top dealmaker, said in an interview. He said the company was focused on improving growth for the second half of the decade, rather than large deals that generate value through cost cuts.

"We think that there are opportunities across all therapeutic areas that we're active in," Malik said, noting the company was agnostic about size for future deals.

In May, Pfizer struck an $11.6 billion deal for migraine drug maker Biohaven Pharmaceutical Holding and recently also completed a $6.7 billion deal to buy Arena Pharmaceuticals.

With the acquisition of Global Blood Therapeutics, Pfizer adds sickle cell disease treatment Oxbryta, which was approved in 2019 and is expected to top $260 million in sales this year. It will also pick up two pipeline assets - GBT601 and inclacumab - targeting the same disease.

Pfizer said if they are all approved, it believes GBT's drugs could generate more than $3 billion in sales annually at their peak.

Sickle cell disease is an inherited blood disorder that affects an estimated 70,000 to 100,000 people in the United States.

GBT Chief Executive Officer Ted Love said Pfizer's resources and multinational infrastructure will allow the company to launch Oxbryta in additional markets and boost its uptake.

"We really have no infrastructure outside of that (U.S. and western Europe) and it takes time and money to build out those infrastructures and Pfizer already has all of it," Love said.

Shares of Global Blood rose 4.5% following the deal announcement. Pfizer shares closed up marginally at $49.41 apiece on Monday.

Flush with cash, Pfizer buys Global Blood Therapeutics in $5.4 billion deal
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Comments (1)
Kate Davis
Kate Davis Aug 08, 2022 10:25AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Buying a Blood Therapeutic company with ****cash. The next Pfizer will control what put in your blood starting from little children. Pfizer is a E V I L!
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email